Voyager Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All VT6.F news ›Voyager Therapeutics (VYGR) Expected to Release Earnings on Monday
Posted by Michael Walen on Nov 2nd, 2026 NASDAQ:VYGR opened at $1.72 on Monday. The firm has a market cap of $105.98 million, a P/E ratio of -0.96 and a beta of 1.28. Voyager Therapeutics has a fifty-two week low of $1.68 and a fifty-two…
Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy
Voyager Therapeutics ( (VYGR) ) has issued an update. The most recent analyst rating on (VYGR) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast…
Voyager Therapeutics (VYGR) Gets a Buy from Wells Fargo
In a report released on October 2, from Wells Fargo maintained a Buy rating on Voyager Therapeutics, with a price target of $10.00. The company... In a report released on October 2, from Wells Fargo maintained a Buy rating on Voyager…
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst
H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Voyager Therapeutics today and set a price target of $25.00. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Alnylam Pharma,…
Canaccord Genuity Keeps Their Buy Rating on Voyager Therapeutics (VYGR)
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Voyager Therapeutics yesterday and set a price target of $12.00. The company’s shares closed yesterday at $3.20. Kulkarni covers the Healthcare sector, focusing on stocks…
Voyager Therapeutics Names Robin Swartz President, Plans CEO Transition in 2027
Voyager Therapeutics (Nasdaq: VYGR), a Lexington, Massachusetts-based biotechnology company developing genetic medicines for neurological diseases, has appointed Robin Swartz president, effective October 20, 2026, as part of a leadership…
Voyager Therapeutics names Robin Swartz as successor to CEO Alfred Sandrock
Voyager Therapeutics names Robin Swartz president, set to become CEO in 2027 after VY1706 Alzheimer’s gene therapy safety data. - Voyager Therapeutics (VYGR) appointed Robin Swartz, its current chief business officer and chief operating…
Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average – Here’s What Happened
Posted by Defense World Staff on Oct 13th, 2026 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.08 and…
TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics yesterday. The company’s shares closed yesterday at $3.13. Nadeau covers the Healthcare sector, focusing on stocks such as Biogen, Voyager Therapeutics, and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- citybiz.co1
- defenseworld.net1
- seekingalpha.com1
- theglobeandmail.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.